Table 2.

– Multivariable Cox regression for factors associated with rPFS and time to CRPC

	rPFS		CRPC
	HR (95% CI)	p value	HR (95% CI)	p value
TP53	1.59 (1.04–2.41)	0.03	1.71 (1.16–2.52)	0.01
DNA double-strand break	1.07 (0.68–1.73)	0.7	1.22 (0.80–1.86)	0.4
WNT	1.24 (0.65–2.36)	0.5	0.94 (0.53–1.67)	0.8
Cell cycle	1.08 (0.59–1.98)	0.8	0.95 (0.50–1.81)	0.9
PTEN/PI3K	0.92 (0.59–1.44)	0.7	0.95 (0.63–1.43)	0.8
Pre-metastasis prostate-specific antigen	1.0006 (1–1.001)	0.2	1.01 (1.001–1.003)	<0.001
Number of lesions	1.05 (1.01–1.10)	0.03	1.08 (1.04–1.12)	<0.001
Gleason grade group	1.08 (0.90–1.29)	0.4	1.52 (1.24–1.86)	<0.001
Location (vs abdominal node)		0.6		0.9
Pelvic node	1.004 (0.47–2.14)		1.28 (0.57–2.87)
Bone	0.74 (0.40–1.38)		1.002 (0.53–1.90)
Visceral	0.64 (0.30–1.39)		1.12 (0.51–2.45)
De novo vs metachronous	1.05 (0.63–1.72)	0.9	5.39 (3.18–8.88)	<0.001

rPFS = radiographic progression-free survival; CRPC = castrate-resistant prostate cancer; HR = hazard ratio; CI = confidence interval.